Document is current

Article History

Accepted: 14 August 2023

First Online: 12 September 2023

Declarations

:

: No funding was received for the preparation of this article.

: Zev A. Binder has an inventorship interest in intellectual property owned by the University of Pennsylvania and has received royalties related to CAR-T therapy in solid tumors. Donald M. O’Rourke is an inventor of intellectual property (US patent numbers 7,625,558 and 6,417,168 and related families) and has received royalties related to targeted ErbB therapy in solid cancers previously licensed by the University of Pennsylvania. Stephen J. Bagley has an inventorship interest in intellectual property owned by Novartis and the University of Pennsylvania: US Patent 62/809,245: “Combination therapies of EGFRvIII chimeric antigen receptors and PD-1 inhibitors”.

: Literature review: Z.A.B., O.Y.T, and S.J.B. Initial draft of manuscript: Z.A.B., O.Y.T, and S.J.B. Critical review and editing of manuscript: Z.A.B., O.Y.T, D.M.O, and S.J.B.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

: Not applicable.